Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin.
Conclusion: The results of our study are promising, and further studies will be necessary to confirm the applicability of eBAT as a supplementary therapy for a variety of sarcomas, carcinomas, and possibly other refractory malignancies that express EGFR and uPAR.
PMID: 30288129 [PubMed]
Source: Clinical Pharmacology: Advances and Applications - Category: Allergy & Immunology Tags: Clin Pharmacol Source Type: research
More News: Adenocarcinoma | Allergy & Immunology | Bone Cancers | Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Osteosarcoma | Ovarian Cancer | Ovaries | Rhabdomyosarcoma | Sarcomas | Study